STANLEY THOMAS CROOKE
Medical Practice in Carlsbad, CA

2005004, Feb 24, 2005

Jun 3, 2004

10/860455

Brenda Baker - Carlsbad CA, US
Anne Eldrup - Danbury CT, US
Muthiah Manoharan - Weston MA, US
Balkrishen Bhat - Carlsbad CA, US
Richard Griffey - Vista CA, US
Eric Swayze - Carlsbad CA, US
Stanley Crooke - Carlsbad CA, US
Thazha Prakash - Carlsbad CA, US

A61K048/00, C12Q001/68, C07H021/02

435006000, 514044000, 536023100

Oligonucleotide compositions comprising first and second oligonucleotides are provided wherein at least a portion of the first oligonucleotide is capable of hybridizing with at least a portion of the second oligonucleotide, at least a portion of the first oligonucleotide is complementary to and capble of hybridizing to a selected target nucleic acid, and at least one of the first or second oligonucleotides includes at least one nucleotide having a modified phosphorous-containing internucleoside linkage. Oligonucleotide/protein compositions are also provided comprising an oligonucleotide complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligonucleotide has a modified phosphorous-containing internucleoside linkage.

2004017, Sep 2, 2004

Nov 4, 2003

10/701257

Brenda Baker - Carlsbad CA, US
Anne Eldrup - Ridgefield CT, US
Muthiah Manoharan - Weston MA, US
Balkrishen Bhat - Carlsbad CA, US
Richard Griffey - Vista CA, US
Eric Swayze - Carlsbad CA, US
Stanley Crooke - Carlsbad CA, US
Thazha Prakash - Carlsbad CA, US

C12Q001/68, C07H021/02, A61K048/00

435/006000, 435/375000, 514/044000, 536/023100

Oligomer compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capble of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes at least two nucleoside having a modified non-phosphorous-containing internucleoside linkage. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least two nucleosides of the oligomer has a modified non-phosphorous-containing internucleoside linkage.

2010004, Feb 18, 2010

Jul 29, 2009

12/511437

Timothy Vickers - Oceanside CA, US
Seongjoon Koo - Carlsbad CA, US
C. Frank Bennett - Carlsbad CA, US
Stanley T. Crooke - Carlsbad CA, US
Nicholas M. Dean - Olivenhain CA, US
Brenda F. Baker - Carlsbad CA, US

C12Q 1/68, C07H 21/02

435 6, 536 245

The present invention provides, inter alia, methods of selecting a single-stranded oligomeric compounds for inhibiting RNA expression, methods of generating double-stranded oligomeric compounds, methods of identifying optimized double-stranded oligomeric compounds, methods of selecting optimized single-stranded oligomeric compounds, methods of selecting optimized double-stranded oligomeric compounds, methods of identifying multifunctional oligomeric compounds, methods for optimizing target region selection for modulation of RNA expression, methods of optimizing expression modulation of RNA, and the like. The present invention further provides oligomeric compounds, 8-80 nucleobases in length targeted to a target RNA, wherein said oligomeric compound hybridizes to said target RNA and inhibits RNA levels by at least 50% in both single-stranded and double-stranded forms, and multifunctional oligomeric compounds.

2013012, May 16, 2013

Oct 29, 2012

13/663176

David J. Ecker - Encinitas CA, US
Richard H. Griffey - Vista CA, US
Rangarajan Sampath - San Diego CA, US
Steven A. Hofstadler - Vista CA, US
John McNeil - La Jolla CA, US
Stanley T. Crooke - Carlsbad CA, US

G06F 19/10

702 19

The present invention relates generally to the field of investigational bioinformatics and more particularly to secondary structure defining databases. The present invention further relates to methods for interrogating a database as a source of molecular masses of known bioagents for comparing against the molecular mass of an unknown or selected bioagent to determine either the identity of the selected bioagent, and/or to determine the origin of the selected bioagent. The identification of the bioagent is important for determining a proper course of treatment and/or irradication of the bioagent in such cases as biological warfare. Furthermore, the determination of the geographic origin of a selected bioagent will facilitate the identification of potential criminal identity.

2004014, Jul 29, 2004

Nov 4, 2003

10/700939

David Ecker - Encinitas CA, US
Herb Boswell - San Marcos CA, US
Stanley Crooke - Carlsbad CA, US

C12Q001/68, C07H021/02

435/006000, 536/023100

Oligomer compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capble of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers has a non-linear secondary structure or is part of a multiple oligomer assembly. Oligonucleotide/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein the oligomer has has a non-linear secondary structure or is part of a multiple oligomer assembly.

2005005, Mar 10, 2005

Jun 3, 2004

10/859825

Brenda Baker - Carlsbad CA, US
Anne Eldrup - Danbury CT, US
Muthiah Manoharan - Weston MA, US
Balkrishen Bhat - Carlsbad CA, US
Richard Griffey - Vista CA, US
Eric Swayze - Carlsbad CA, US
Stanley Crooke - Carlsbad CA, US

C12Q001/68, C07H021/02, A61K048/00

435006000, 514044000, 536023100

Oligomer compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capble of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes at least one nucleotide comprising a chimeric organic composition. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide comprising a chimeric organic composition.

2009018, Jul 16, 2009

Oct 30, 2007

11/929930

David J. Ecker - Encinitas CA, US
Richard H. Griffey - Vista CA, US
Rangarajan Sampath - San Diego CA, US
Steven A. Hofstadler - Oceanside CA, US
John McNeil - La Jolla CA, US
Stanley T. Crooke - Carlsbad CA, US
Lawrence Blyn - Mission Viejo CA, US
Thomas Hall - Oceanside CA, US
Yun Jiang - Carlsbad CA, US
James C. Hannis - Vista CA, US
Neill White - Encinitas CA, US
Vivek Samant - Encinitas CA, US
Mark W. Eshoo - Solana Beach CA, US
Jared James Drader - Carlsbad CA, US

IBIS BIOSCIENCES, INC. - Carlsbad CA

G01N 33/48, G06F 19/00

702 19

The present invention provides methods for rapid forensic analysis of mitochondrial DNA and methods for characterizing heteroplasmy of mitochondrial DNA, which can be used to assess the progression of mitochondrial diseases.

5248670, Sep 28, 1993

Feb 26, 1990

7/485297

Kenneth G. Draper - San Marcos CA
David J. Ecker - Carlsbad CA
Christopher K. Mirabelli - Encinitas CA
Stanley T. Crooke - Carlsbad CA

ISIS Pharmaceuticals, Inc. - Carlsbad CA

A61K 3170, C07H 2100, C07H 2102, C07H 2104

514 44

Antisense oligonucleotides are disclosed having a length of 15-30 nucleotides containing the CAT sequence and hybridizable to herpes simplex virus type I gene UL13, UL39, or UL40. These antisense oligomers inhibit the replication of the virus at least three-fold. Pharmaceutical compositions containing these oligonucleotides as the active ingredients are also disclosed.

5457189, Oct 10, 1995

Mar 31, 1992

7/860925

Stanley T. Crooke - Carlsbad CA
Christopher K. Mirabelli - Encinitas CA
David J. Ecker - Carlsbad CA
Lex M. Cowsert - Carlsbad CA

Isis Pharmaceuticals - Carlsbad CA

C07H 2104, A61K 4800

536 245

Oligonucleotides are provided which are capable of antisense interaction with messenger RNA of papillomavirus. Such oligonucleotides or oligonucleotide analogs can be used for diagnostics and therapeutics as well as for research purposes. In accordance with preferred embodiments of this invention, oligonucleotide ISIS 2105 is provided which hybridizes with selected messenger RNA from a human papillomavirus. The oligonucleotide is able to inhibit the function of the RNA, and accordingly is useful for therapy for infections by such papillomavirus. In accordance with a preferred embodiment, portions of the papillomavirus are targeted for antisense attack. Thus oligonucleotides are preferably provided which hybridize with the E2, E6 and E7 messenger RNAs.

7781162, Aug 24, 2010

Sep 11, 2003

10/660122

David J. Ecker - Encinitas CA, US
Richard H. Griffey - Vista CA, US
Rangarajan Sampath - San Diego CA, US
Steven A. Hofstadler - Oceanside CA, US
John McNeil - La Jolla CA, US
Stanley T. Crooke - Carlsbad CA, US

Ibis Biosciences, Inc. - Carlsbad CA

C12Q 1/68, C12P 19/34, C07H 21/04

435 6, 435 912, 536 2433

The present invention provides methods of: identifying pathogens in biological samples from humans and animals, resolving a plurality of etiologic agents present in samples obtained from humans and animals, determining detailed genetic information about such pathogens or etiologic agents, and rapid detection and identification of bioagents from environmental, clinical or other samples.